Earlier on August 19, Erik Woodring of Morgan Stanley joined CNBC’s ‘The Exchange’ to discuss the most under-owned tech stocks and what’s behind the bifurcation in the sector. Woodring believes that mega-cap tech is under-owned in the market, as Morgan Stanley revealed that these stocks are the most under-owned by actively managed funds in over 16 years. The gap between the portfolio weightings of these stocks and their weightings in the S&P 500 index widened significantly in the second quarter. Despite thi ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam Pharmaceuticals announced new data analyses from the HELIOS-B Phase 3 study of its RNAi therapeutic, called AMVUTTRA (vutrisiran), presented at the Heart Failure Society of America/HFSA Annual Scientific Meeting 2025. The findings showed a reduction in gastrointestinal/GI events, which is a multisystem manifestation of transthyretin-mediated amyloidosis cardiomyopathy/ATTR-CM. Compare ...

PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding clinical deve ...

Sep 30, 2025 4:11 PM Eastern Daylight Time Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock Share WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intend ...

TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at htt ...

New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen Therapertics”), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, from its client Faraday Future Intelligent Electric Inc. (NASDA ...

We recently published 10 Stocks With 10-60% Upside. Merus NV (NASDAQ:MRUS) is one of the top performers on Monday. Shares of Merus NV soared to a new record high on Monday, as investors gobbled up shares following news that it was set to be acquired by Genmab AS at a 41-percent premium. In a statement, Genmab AS said that it entered into an agreement with Merus NV (NASDAQ:MRUS) for the acquisition of the latter, through its subsidiary, Purchaser, for $8 billion. Merus (MRUS) Soars to New High on Genmab ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that bought securities between August 10, 2023, and June 25, 2025, inclusive (the “Class Period”). Altimmune investors have until October 6, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) on September 12 with a Neutral rating and a $38 price target. Is Chevron Corporation (CVX) the Low Volatility Stock to Buy According to Billionaire Ken Fisher? However, Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 16, setting a price target of $163.00. Similarly, Seamus Fernandez fr ...